-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Neutral on Keros Therapeutics, Maintains $15 Price Target

Benzinga·05/30/2025 13:24:18
Listen to the news
Wedbush analyst Yun Zhong reiterates Keros Therapeutics (NASDAQ:KROS) with a Neutral and maintains $15 price target.